

Association Between Telehealth Use and 30-day Medicare Spending

Chad Ellimoottil MD, MS^{1,2,3}, Ashwin J. Kulkarni², Ziwei Zhu MS,^{1,3} Rodney L. Dunn MS^{1,3}, Chiang-Hua Chang PhD, MS^{3,4}, Elena Chun MS^{1,3}, Hechuan Hou^{3,4}, James D. Lee MD, MPH^{3,5}, Jeffrey S. McCullough PhD^{3,6}, Michael P. Thompson PhD^{3,4}

1. Department of Urology, University of Michigan, Ann Arbor
2. University of Michigan Medical School, Ann Arbor
3. Institute for Healthcare Policy & Innovation, Ann Arbor
4. Department of Cardiac Surgery, University of Michigan, Ann Arbor
5. Department of Internal Medicine, University of Michigan, Ann Arbor
6. Department of Health Management and Policy, University of Michigan, Ann Arbor

Corresponding author:

Chad Ellimoottil, MD, MS

Associate Professor, University of Michigan Department of Urology

Medical Director of Virtual Care, University of Michigan Health

Institute for Healthcare Policy and Innovation

2800 Plymouth Rd, Bldg 16, 1st Floor, Room 112W, Ann Arbor, MI 48109

cellimoo@med.umich.edu

Office: 630-440-4458

ABSTRACT

Importance: Despite the widespread use of telehealth among Medicare beneficiaries secondary to the COVID-19 pandemic, few studies have evaluated telehealth's impact on downstream spending.

Objective: This retrospective cohort study compares the overall spending, rates of return visits, laboratory tests, and imaging procedures within 30 days for Medicare fee-for-service patients who underwent in-person and telehealth evaluations between July 1, 2020 and December 31, 2022.

Design: A large-scale retrospective cohort study using propensity score matching

Setting: Patients with no prior visits and 30-day episodes of care initiated by telehealth or in-person visits from July 1, 2020 through December 31, 2022.

Participants: This study included 100% of Medicare fee-for-service beneficiaries who are aged >65 years while excluding those with Medicare Advantage coverage and those without continuous Medicare Parts A and B.

Exposure(s): Comparison of index visits initiated by telehealth versus in-person visits.

Primary outcome: Adjusted 30-day total spending.

Secondary outcomes: 30-day rates of return visits, laboratory tests, and imaging.

Results: The study included 30,079,958 participants with 36,709,528 and 429,891,125 episodes initiated by telehealth and in-person visits, respectively. The mean age was 76 for telehealth and 75 years for in-person. Telehealth-initiated visits were associated with

lower 30-day spending (\$260 vs. \$342; net: -\$82), though return visit rates were higher for telehealth (16.1% vs. 14.1%). Both lab test rates (7.8% vs. 24.2%) and imaging rates (3.5% vs 7.8%) were lower for telehealth-initiated care episodes compared to in-person-initiated care episodes.

Conclusions and Relevance: Telehealth-initiated episodes of care were associated with lower 30-day Medicare spending and reduced utilization of labs and imaging. These findings suggest that telehealth, when used as a substitute for office visits, may reduce overall Medicare spending.

INTRODUCTION

Since March 2020, telehealth has become an integral part of healthcare delivery [1,2]. Among Medicare beneficiaries, the use of telehealth services surged in early 2020, followed by a gradual decline [3]. In 2022, 43% of patients had at least one evaluation and management visit via telehealth [4]. This expansion was facilitated by telehealth coverage flexibilities introduced during the national public health emergency. The Consolidated Appropriations Act, 2023, extended several key Medicare telehealth policies through December 31, 2024 [5]. However, the extension of these flexibilities beyond that date remains uncertain. There is, however, positive momentum, as demonstrated by the House Ways and Means Committee's unanimous passage of the Preserving Telehealth, Hospital, and Ambulance Access Act (H.R. 8261) with a 41-0 vote. If enacted, this legislation would extend many of the current Medicare telehealth flexibilities through the end of 2026 [6]. Additionally, on May 16, 2024, the House Energy and Commerce Subcommittee on Health passed the Telehealth Modernization Act (H.R. 7623) with a 21-0 vote, which would remove geographic originating site restrictions for two years, and the Telehealth Enhancement for Mental Health Act (H.R. 7858) [7,8]. These bills, unanimously approved by bipartisan Congressional committees, highlight the broad acceptance of telehealth as a critical component of healthcare delivery.

While there is bipartisan enthusiasm for making temporary telehealth coverage policies permanent, the lack of data on the impact of telehealth on Medicare spending hinders policymaking. In fact, concerns over telehealth's effect on Medicare expenditures are a

primary reason why extensions have been granted instead of establishing permanent policies. The Congressional Budget Office has raised several unresolved questions regarding telehealth, particularly whether these services substitute for in-person Medicare services or are provided in addition to them [9]. A crucial question is whether the use of telehealth services influences beneficiaries' likelihood of utilizing downstream services. On one hand, insufficient telehealth visits may lead to redundant expenses and potentially require additional diagnostic procedures. On the other hand, telehealth could reduce Medicare spending by enabling early intervention, thereby reducing the need for emergency room visits and hospital admissions. Furthermore, telehealth might lessen the frequency of unnecessary diagnostic tests often performed during physical appointments, addressing the issue of "convenience testing" without clear medical justification.

Several prior studies have investigated the effects of telehealth on healthcare expenditures. An analysis by the Medicare Payment Advisory Commission found that health service areas with more intensive telehealth use experienced slightly higher overall healthcare costs per beneficiary [10]. Additionally, Nakamoto et al. observed a \$248 increase in per-patient-per-year spending associated with telemedicine use across health systems [11]. While both studies employed the difference-in-difference technique to control for secular trends and enhance causal inference, directly attributing the rise in costs to telehealth remains challenging due to the aggregated nature of the outcomes [12].

Our approach to addressing this limitation is to conduct an episode-level study. By directly examining the use of return visits, labs, and imaging within 30 days of a telehealth visit compared to similar in-person visits, we aim to expand on the existing literature by focusing on the downstream costs that follow a telehealth encounter.

METHODS

Data Sources and Population

We utilized a dataset comprising all claims for 100% national fee-for-service Medicare beneficiaries. The study encompassed patients who received care between July 1, 2020, and December 31, 2022. By starting our study period on July 1, 2020, we aimed to minimize the influence of care disruptions that occurred early during the pandemic. To construct our dataset, we used the Medicare Master Beneficiary Summary and excluded beneficiaries who were less than 65 years old or above 99 years old, not continuously enrolled in both Medicare Part A and Part B, as well as those with Medicare Advantage coverage for the specified year. This study followed the STROBE reporting guidelines and was determined to be exempt from review by the University of Michigan Institutional Review Board [13].

Identifying Episodes of Care

Using the Carrier file, we identified outpatient evaluation and management (E&M) visits received by our study population, focusing on Berenson-Eggers Type of Service codes (M1A, M1B, M5B, M5C, M5D). To identify telehealth services, we took two steps. First, we looked for outpatient E&M services with the appropriate modifier codes (GT, GQ, 95)

or place of service code (02). Secondly, we ensured that the Healthcare Common Procedure Coding System (HCPCS) codes associated with the identified claims were included in Medicare's list of eligible telehealth services for the corresponding year or were classified by Medicare as phone services.

We then mapped each E&M visit to a diagnosis category using the Clinical Classifications Software Refined (CCSR, v2022.1) based on the primary diagnosis code. Developed as part of the Healthcare Cost and Utilization Project, CCSR aggregates 70,000 International Classification of Diseases, 10th Revision, Clinical Modification/Procedure Coding System (ICD-10-CM/PCS) codes into over 530 clinically meaningful diagnosis categories.

For defining an episode of care, we considered the thirty-day window following an index outpatient visit. Index visits were identified as those with no other outpatient E&M visits in the same diagnosis category as the initial code within the preceding sixty days. In cases where we found multiple visits for the same primary diagnosis code on the same day, we prioritized telehealth visits first, followed by office visits for the index visit definition. A maximum of one episode was constructed for each beneficiary-CCSR combination every 60 days.

Outcome

Our primary outcome was 30-day total Medicare payment, defined as the total payments from the same CCSR paid by the Medicare program during the index visit and up to 29 days after the index visit. This outcome did not include coinsurance or payments made by the patient because our study is focused on Medicare spending. We examined total Part B payments, outpatient payments, and inpatient payments during the 30-day period of time.

In addition to cost, we also examined several utilization outcomes. First, we examined the 30-day related return visit rate, which we defined as the rate of episodes where there was a second office visit for the same CCSR within 29 days after the index visit. Similarly, we examined the rate of episodes that included related imaging and labs during the index visit day or within 29 days after the day of the index visit. Imaging and lab tests were identified using Berenson-Eggers Type of Service (BETOS) categories (I and T, respectively). Imaging and lab tests were considered “related” if the diagnosis code category for primary diagnosis associated with the test was in the same CCSR as the index visit.

Statistical Analysis

We performed an episode-level analysis where we compared our primary and secondary outcomes between episodes of care that were initiated by an in-person index visit versus a telehealth index visit. To account for the differences in the two groups, we performed propensity score matching. To do so, we first built a multivariable logistic regression model to predict whether the episode of care would be telehealth or in-

person. In this model, we included the following predictors: CCSR, gender, age, race, rural, dual eligibility, and Hierarchical Condition Category Risk Adjustment Factor (HCC RAF) scores. Using this model, we obtained the predicted propensity that the episode would be a telehealth visit. We then performed nearest neighbor matching with replacement to find one control within each CCSR for each telehealth episode. After creating the two balanced cohorts, we performed a paired t-test for each continuous outcome and McNemar's test for each categorical outcome to evaluate differences between telehealth and in-person episodes.

Sensitivity Analysis

We performed several sensitivity analyses to assess the robustness of our results. First, we examined outcomes stratified by telehealth propensity quintiles and selected CCSR categories in mental health and non-mental health. We also assessed the outcomes using matching without replacement where each in person control episode is matched to a maximum of one telehealth episode.

RESULTS

Study Population

The study included 30,079,958 participants with 36,709,528 and 429,891,125 episodes initiated by telehealth and in-person visits, respectively. Mean age was 76 for telehealth group and 75 for in-person group, with the telehealth group having higher risk adjustment factor (RAF) scores (1.29 vs. 0.83) correlating with increased average

comorbidities, higher proportion of female patients (59% vs. 54%), and a lower proportion of rural patients (17% vs. 27%).

30-day Spending

Telehealth-initiated visits were associated with lower 30-day spending (\$260 vs. \$342; difference, -\$82 [95% CI: -83 to -82]) (**Table 1**). This decreased spending was consistent across multiple cost categories. Telehealth was associated with lower 30-day inpatient costs (\$59 vs. \$71, -\$11 [95% CI: -12 to -11]), lower 30-day outpatient costs (\$56 vs. \$76, -\$20 [95% CI: -21 to -20]), and lower 30-day Medicare Part B costs (\$145 vs. \$196, -\$51 [95% CI: -51 to -50]). Spending was consistently lower for telehealth across all propensity quintiles (**Appendix Table 1**).

30-day Return-Visit Rates

Rates of 30-day return visits for related conditions were higher for telehealth-initiated visits compared to in-person initiated visits (16.1% vs. 14.1%, +2.0% [95% CI: 2.0 to 2.0]) (**Table 2**). All quintiles show an increase in return visit rates for telehealth (**Appendix Table 2**).

30-day Imaging and Lab Tests Rates

In contrast to return visit rates, rates of imaging tests completed within 30 days of the index visit were lower for telehealth-initiated visits compared to in-person initiated visits (3.5% vs. 7.8%, -4.4% [95% CI: -4.4 to -4.3] **(Table 2)**). Imaging rates were largely variable by propensity quintiles, though each quintile did show a significant decrease in imaging rates for telehealth visits **(Appendix Table 2)**. To an even greater degree, the rate of lab tests completed within 30 days was also lower for telehealth-initiated visits (7.8% vs. 24.2%, -16.4% [95% CI: -16.4 to -16.4]). This pattern is consistent across propensity quintiles, with differences between telehealth and in person visits ranging from 8.9% to 23.7%. Overall, telehealth-initiated visits were associated with lower imaging and lab utilization.

Mental Health CCSRs

The three largest mental health CCSR categories included depression-related disorders, anxiety and fear-related disorders, and trauma-and stressor-related disorders. In depression-related disorders (MBD002), telehealth-initiated visits were associated with lower 30-day spending (\$220 vs. \$271, -\$51). However, telehealth-initiated visits were associated with higher 30-day spending in both anxiety and fear-related disorders (MBD005) (\$167 vs. \$146, +\$20) and trauma and stressor-related disorders (MBD007) (\$241 vs. \$214, +\$28). For all three categories, telehealth-initiated visits had higher return visit rates but lower imaging and lab test rates **(Appendix Table 3)**.

Non-Mental Health Conditions

The three largest non-mental health CCSR categories included essential hypertension, sleep-wake disorders, and both infective and non-infective spondyloarthropathies. In all of these categories, telehealth-initiated visits were associated with lower 30-day spending: essential hypertension (CIR007) (\$112 vs. \$126, -\$14), sleep wake disorders (NVS016) (\$107 vs. \$155; -\$47), and spondyloarthropathies (MUS011) (\$416 vs. \$568, -\$152). For all three categories, telehealth-initiated visits once again had higher return visit rates but lower imaging and lab test rates (**Appendix Table 4**).

Sensitivity Analysis

When performing a sensitivity analysis to assess the outcomes using matching without replacement, we found that our results were consistent. Specifically, telehealth-initiated visits were associated with lower spending, higher return visits, and lower imaging and lab tests (**Appendix Table 5**).

DISCUSSION

In this analysis of 30-day Medicare spending for telehealth and in-person episodes of care, we found that episodes initiated via telehealth were associated with lower 30-day expenditures compared to those initiated in person. This reduction in spending was consistent across inpatient, outpatient, and Part B categories. Although telehealth episodes resulted in a higher frequency of 30-day follow-up visits, they were associated

with fewer laboratory and imaging tests, likely contributing to the overall decrease in 30-day Medicare spending for telehealth-initiated care episodes.

Our finding that telehealth is associated with lower Medicare spending contrasts with the conclusions drawn by the Medicare Payment Advisory Commission (MedPAC) and Nakamoto et al. [10,11,14]. MedPAC analyzed the 6-month total cost of care for Part A and/or B services per fee-for-service (FFS) Medicare beneficiary across hospital service areas (HSAs) with varying levels of telehealth use (low, medium, or high terciles). They found that HSAs with high telehealth use had a higher total cost of care, with an additional \$164.99 per beneficiary over six months compared to areas with low telehealth use. MedPAC employed a difference-in-difference (DiD) analysis to improve causal inference and adjust for secular trends.

Similarly, Nakamoto et al. used a DiD framework but applied it to a health system-level analysis. Their research revealed that Medicare patients receiving care in health systems within the highest quartile of telemedicine use experienced a \$248 increase in per-patient, per-year spending. The primary advantage of the DiD approach is its ability to control for unobserved, time-invariant confounders. By comparing changes in outcomes over time between treatment groups (high telehealth tercile or quartile) and control groups (low telehealth use), the DiD method effectively removes the influence of factors that remain constant over time, isolating the impact of telehealth use on outcomes.

However, there are also limitations to this approach. First, unobserved differences between HSAs and health systems that evolved over time, especially during the pandemic, could have confounded the results, leading to biased estimates of the association between telehealth use and outcomes. This is particularly relevant given the substantial changes in healthcare delivery beyond telehealth during this period [15]. Second, aggregating data at the HSA level may obscure important variations at the individual or provider level. Differences in telehealth use within HSAs or variations in how telehealth was implemented across health systems could lead to heterogeneous effects that the DiD approach might not capture, potentially resulting in an oversimplified interpretation of the results.

In response to these limitations, our study focused on a shorter interval—30-day care episodes—hypothesizing that a more confined time frame might better correlate downstream expenditures with the initial telehealth encounter. Additionally, we employed propensity score matching to enhance our dataset by accounting for inherent cost differences between telehealth and in-person initiated episodes. However, like a DiD analysis, a propensity score-based episode analysis may still be subject to unmeasured confounding variables, underscoring the importance of utilizing diverse analytical strategies to inform policy decisions.

In addition to reduced Medicare spending, our study also found a significant decrease in both imaging and lab test rates within the telehealth cohort. While multiple prior studies have examined healthcare utilization, including lab tests and imaging, for audio versus

video telehealth visits, none have directly compared these metrics with in-person care [16,17]. Although it's not entirely clear whether the reduced utilization of labs and imaging is the sole driver of decreased spending, this seems likely given the increased frequency of 30-day return visits following telehealth-initiated care episodes in our study. This finding is consistent with previous literature from our group and others. For example, a 2021 study on follow-up care for acute respiratory infections reported that 10.3% of telehealth consultations led to subsequent care, compared to 5.9% for in-person visits [18].

Limitations

Our study has several limitations. First, our study utilized Medicare Fee-for-Service data; hence, our results may not extend to patients with commercial payor or Medicare Advantage plans. However, understanding telehealth's impact on Medicare spending is crucial for Medicare policy decision-making. Second, despite employing matching to equilibrate our control and intervention groups, unmeasured confounders may still bias our findings. Third, the scope of our analysis was confined to the costs and utilization associated with telehealth, without evaluating the quality of care between telehealth and in-person visits.

These limitations notwithstanding, our study offers critical insights for healthcare providers, insurance payers, and, most importantly, policymakers engaged in ongoing debates regarding the permanent coverage of telehealth services. In the context of Medicare spending, understanding telehealth's financial implications remains

paramount. Our research finds that telehealth visits are not linked to increased 30-day subsequent healthcare costs. This finding is primarily attributed to the observed decrease in laboratory tests and imaging procedures. Such evidence is poised to inform policy discussions, underscoring the cost-effectiveness of telehealth in contemporary healthcare delivery models.

CONCLUSION

In this three-year retrospective cohort study, we found that telehealth-initiated episodes of care were associated with lower 30-day Medicare spending. Additionally, the telehealth cohort exhibited lower rates of lab and imaging utilization, accompanied by higher return visit rates, trends observed across both mental health and non-mental health conditions. These findings suggest that telehealth may not contribute to increased downstream spending. This evidence is crucial for healthcare policymakers as they consider the financial implications of telehealth coverage in the context of codifying permanent telehealth legislation within Medicare.

REFERENCES

1. Medicare Beneficiaries' Use of Telehealth in 2020: Trends by Beneficiary Characteristics and Location. (n.d.). ASPE.
<https://aspe.hhs.gov/reports/medicare-beneficiaries-use-telehealth-2020>
2. Outpatient telehealth use soared early in the COVID-19 pandemic but has since receded - Peterson-KFF Health System Tracker. (2024, March 23). Peterson-KFF Health System Tracker.
3. Saharkhiz M, Rao T, Parker-Lue S, Borelli S, Johnson K, Cataife G. Telehealth Expansion and Medicare Beneficiaries' Care Quality and Access. *JAMA Netw Open*. 2024;7(5):e2411006. doi:10.1001/jamanetworkopen.2024.11006
4. Chang E, Penfold RB, Berkman ND. Patient Characteristics and Telemedicine Use in the US, 2022. *JAMA Netw Open*. 2024;7(3):e243354. doi:10.1001/jamanetworkopen.2024.3354
5. H.R.2617 - 117th Congress (2021-2022): Consolidated Appropriations Act, 2023, H.R.2617, 117th Cong. (2022), <https://www.congress.gov/bill/117th-congress/house-bill/2617>.
6. H.R.8261 - 118th Congress (2023-2024): Preserving Telehealth, Hospital, and Ambulance Access Act, H.R.8261, 118th Cong. (2024), <https://www.congress.gov/bill/118th-congress/house-bill/8261>.
7. H.R.7623 - 118th Congress (2023-2024): Telehealth Modernization Act of 2024, H.R.7623, 118th Cong. (2024), <https://www.congress.gov/bill/118th-congress/house-bill/7623/text>.
8. H.R.7858 - 118th Congress (2023-2024): Telehealth Enhancement for Mental Health Act of 2024, H.R.7858, 118th Cong. (2024), <https://www.congress.gov/bill/118th-congress/house-bill/7858>.
9. Cohen M. Medicare's Coverage of Telehealth: Considerations From the Congressional Budget Office. Presented at: 2024 AcademyHealth Annual Research Meeting; May 2024. <https://www.cbo.gov/system/files/2024-06/60458-Telehealth.pdf>
10. Medicare Payment Advisory Commission. Report to the Congress: Medicare and the Health Care Delivery System. Washington, DC: MedPAC; June 2023.
11. Nakamoto CH, Cutler DM, Beaulieu ND, Uscher-Pines L, Mehrotra A. The Impact Of Telemedicine On Medicare Utilization, Spending, And Quality, 2019–22. *Health Aff (Millwood)*. 2024;43(5): 691-700.
12. Reed M, Huang J, Somers M, Hsueh L, Graetz I, Millman A, Muelly E, Gopalan A. Telemedicine Versus In-Person Primary Care: Treatment and Follow-up Visits. *Ann Intern Med*. 2023;176(10):1349-1357. doi: 10.7326/M23-1335.
13. von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandembroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. *J Clin Epidemiol*. 2008;61(4):344-349. doi: 10.1016/j.jclinepi.2007.11.008.
14. Medicare Payment Advisory Commission Public Meeting. Telehealth in Medicine: Status Report. Washington, DC: MedPAC; April 11 2024.
15. Saharkhiz M, Rao T, Parker-Lue S, Borelli S, Johnson K, Cataife G. Telehealth Expansion and Medicare Beneficiaries' Care Quality and Access. *JAMA Netw Open*. 2024;7(5):e2411006. doi:10.1001/jamanetworkopen.2024.11006

16. Juergens N, Huang J, Gopalan A, Muelly E, Reed M. The association between video or telephone telemedicine visit type and orders in primary care. *BMC Med Inform Decis Mak.* 2022;22(1):302. doi: 10.1186/s12911-022-02040-z.
17. Huang J, Gopalan A, Muelly E, Hsueh L, Millman A, Graetz I, Reed M. Primary care video and telephone telemedicine during the COVID-19 pandemic: treatment and follow-up health care utilization. *Am J Manag Care.* 2023;29(1):e13-e17. doi: 10.37765/ajmc.2023.89307.
18. Li KY, Zhu Z, Ng S, Ellimoottil C. Direct-To-Consumer Telemedicine Visits For Acute Respiratory Infections Linked To More Downstream Visits. *Health Aff (Millwood).* 2021;40(4):596-602. doi: 10.1377/hlthaff.2020.01741.

TABLES

Table 1 - 30 Day Cost Composition of In-Person vs. Telehealth Initiated Care Episodes


	In Person	Telehealth	Difference	95% Confidence Intervals for Difference	P Value
Inpatient 30D Cost	\$71	\$59	-\$11	(-\$12, -\$11)	<0.001
Outpatient 30D Cost	\$76	\$56	-\$20	(-\$21, -\$20)	<0.001
Part B 30D Cost	\$196	\$145	-\$51	(-\$51, -\$50)	<0.001
Total 30D cost	\$342	\$260	-\$82	(-\$83, -\$82)	<0.001

Table 2 - 30 Day Return Visit, Imaging, and Lab Test Utilization Rates for In-Person vs. Telehealth Initiated Episodes

	In Person	Telehealth	Difference	95% Confidence Intervals for Difference	P Value
Return Visit Rate	14.1%	16.1%	2.0%	(2.0%, 2.0%)	<0.001
Image	7.8%	3.5%	-4.4%	(-4.4%, -4.3%)	<0.001
Test	24.2%	7.8%	-16.4%	(-16.4%, -16.4%)	<0.001


FIGURES

Figure 1 - 30-day Medicare Spending of In-Person vs. Telehealth Initiated Episodes



Caption: Sample includes all Medicare fee-for-service patients who underwent in-person and telehealth evaluations for outpatient care between July 1, 2020 and December 31, 2022. 30-day Medicare spending includes Medicare payments for related Part B, Outpatient and Inpatient expenses.

Figure 2 - 30-day Return Visit, Imaging, and Lab Test Utilization Rates for In-Person vs. Telehealth Initiated Episodes



Caption: Sample includes all Medicare fee-for-service patients who underwent in-person and telehealth evaluations for outpatient care between July 1, 2020 and December 31, 2022.